NeuroDerm says Parkinson’s drug shows promise in study

(Reuters) – NeuroDerm Ltd said data from a mid-stage study suggested that a higher dose of its Parkinson’s drug could provide an alternative to treatments that require surgery, sending its shares soaring 34 percent premarket. The trial evaluated two liquid formulations of the drug, levodopa/carbidopa (LD/CD), in 16 patients with an advanced form of the disease to assess its capacity to reduce Parkinson’s-related motor complications, the Israel-based company said. …
Go to Source